US2013130993A1PendingUtilityA1
Pimap39 modulates inflammatory response
Est. expiryJun 26, 2028(~1.9 yrs left)· nominal 20-yr term from priority
C07K 14/001A61K 38/00A61P 31/00A61P 29/00C07K 14/47
44
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a novel peptide sequence named PIMAP39 (herein referred to as SEQ ID NO.: 1) and methods of use of the novel sequence and functional variants thereof. The present invention also relates to methods for reducing and/or modulating inflammatory responses by administration of the peptide of the present invention. Furthermore, the present invention relates to the modulation of the expression of cytokines effected as part of an inflammatory response by administration of the peptide of the present invention.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of reducing an inflammatory response in a subject, the method comprising administering to the subject an effective amount of a composition comprising an amino acid sequence consisting of SEQ ID NO.: 1 in a pharmaceutically acceptable carrier.
2 . The method of claim 1 , wherein said reduction in an inflammatory response is detected by reduced levels of one or more of TNF-α and IL-1β.Join the waitlist — get patent alerts
Track US2013130993A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.